SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry.
SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets.
SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
SVMPharma also provides Global RWE, Patient Real World Outcomes, and Big Data Analytics.
SVMPHARMA UK LIMITED is part of SOLVERMINDS SOLUTIONS AND TECHNOLOGIES, a global product development and technology company specialising in enterprise application and analytics solutions. Since its inception in September 2003, the company has been at the forefront of delivering innovative solutions to customers.
With a team of 300+ developers, testers and project managers based in India, Malaysia, Denmark and United Kingdom, its team can provide global coverage to its clients. The applications developed by SOLVERMINDS are used in 80+ countries.
Meet SVMPharma at:
30th Annual PM Society Awards London
eyeforpharma Market Access & Real World Evidence EU Summit 2016 Amsterdam
Meet SVMPharma at:
29th Annual PM Society Awards London
Inaugural SVMPharma and talkhealth RWE PCOS Seminar London
3rd Annual Real World Evidence Europe 2015 by eyeforpharma Amsterdam
20th Congress of the European Hematology Association (EHA) Vienna
ISPOR 18th Annual European Congress Milan
Publications and Presentations
Plant BJ, Downey D, Eustace JA, Gunaratnam C, Haworth C, Jones A, McKone, Peckham D, Ketchell I, and Bilton D. Inhaled aztreonam lysine (Cayston) therapy significantly improves lung function, weight, hospitalisations and exacerbation rates prospectively–an Irish and UK real world experience. 37th European Cystic Fibrosis Congress, Gothenburg 11-14 June 2014 Link
Dickerson S, Bantel C, and Mehta V. Fixed-Dose Combination Oxycodone/ Naloxone Reduces Constipation, Improves Quality of Life and Reduces Laxative Use: Real World Evidence from the Targinact® Treatment Evaluator (TTE). British Pain Society ASM 21-23 April 2015 Link
Cornford P, Jefferson K, Cole O, Gilbody JS, Nayar V and Auddy G. Switching to a 6-monthly triptorelin formulation for prostate cancer (PCa) reduces patient–NHS interactions and hospital resource use: Real World Evidence (RWE) from Project DESERVE (DEcapeptyl SERVice Evaluation). ISPOR 18th Annual European Congress, Milan 7-11 November 2015 Link
Horsley W, Nayar V, and Auddy G. Natalizumab use in multiple sclerosis: a Real World Evidence (RWE) analysis of its impact on NHS resources in England. ISPOR 18th Annual European Congress, Milan 7-11 November 2015 Link